RxDoctor Payments DataLook up a doctor →

Debra Davis

Acute Care · Foley, ALNPI 1417117953

Payments from drug & device makers

$30,509in general payments, 2019–2025

Across 566 payments — averaging $53.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$20K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Bayer$933
  • AstraZeneca$820
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$13,83045%
  • Travel & lodging$5,47118%
  • Food & beverage$11,18837%
  • Education$200%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,509 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$47,185
Medicare patients
232
Services billed
16,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide128$146,882
OzempicSemaglutide89$118,212
JardianceEmpagliflozin24$22,746
XareltoRivaroxaban14$16,372
FarxigaDapagliflozin Propanediol13$12,047
Tresiba Flextouch U-100Insulin Degludec17$9,931
TrulancePlecanatide14$8,060
SynthroidLevothyroxine Sodium87$7,733
ProgesteroneProgesterone, Micronized128$6,314
Celecoxib93$5,013
Estradiol (Twice Weekly)Estradiol35$2,339
Bupropion XlBupropion Hcl85$2,202
Omeprazole147$2,184
Omega-3 Acid Ethyl Esters12$1,942
Levothyroxine Sodium225$1,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,415$146,882128 claims
Novo NordiskOzempic$1,880$118,21289 claims
Boehringer IngelheimJardiance$81$22,74624 claims
Johnson & JohnsonXarelto$430$16,37214 claims
AstraZenecaFarxiga$820$12,04713 claims
AbbVieSynthroid, Armour Thyroid$1,711$8,447103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.

Other acute care in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →